A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

The European Medicines Agency has said no to approving a new drug for Alzheimer's disease in the EU. Aducanumab does not appear to be effective at treating adults with early-stage symptoms, the ...

A US drug company says it has created the first therapy that could slow Alzheimer's disease, and it is now ready to bring it to market. Currently, there are no drugs that can do this - existing ...

A new Alzheimer’s therapy has shown potential in the first human trials. Researchers at the West Virginia University ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

A Boston College Center for Retirement Research report looks at the financial implications for Medicare of Alzheimer's drug Aduhelm The recent controversy over Alzheimer’s treatment Aduhelm—criticized ...

Biogen’s treatment for Alzheimer’s was initially regarded as a major treatment breakthrough. Now, only three years later, Ben Hargreaves finds that the abortive launch holds lessons across the ...

An advisory committee to the Ministry of Health, Labour and Welfare (MHLW) has declined to approve Aduhelm (aducanumab), saying the data from its two main clinical trials is hard to interpret, and ...